Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Quehenberger

Showing results (71-80 of 134) with videos related to

Pageof 14
Sort By:
Blood|January 24, 2004
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolismSabine Eichinger, Verena Schönauer, Ansgar Weltermann, et al.
British Journal of Haematology|November 18, 2003
Is the determination of anti-beta2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome?Kety Hsieh, Paul Knöbl, Claudia Rintelen, et al.
JAMA|August 28, 2003
D-dimer levels and risk of recurrent venous thromboembolismSabine Eichinger, Erich Minar, Christine Bialonczyk, et al.
Biochemia Medica|September 14, 2017
Testing lupus anticoagulants in a real-life scenario - a retrospective cohort studyFranz Ratzinger, Tanja Panic, Helmuth Haslacher, et al.
Research and Practice in Thrombosis and Haemostasis|December 29, 2025
High prevalence of factor XIII deficiency and its association with bleeding in extracorporeal membrane oxygenation patients: an observational study from a prospectively compiled biobankAndrea Kornfehl, Roman Brock, Peter Quehenberger, et al.
Stroke|June 4, 2005
Prognostic impact of fibrinogen in carotid atherosclerosis: nonspecific indicator of inflammation or independent predictor of disease progression?Schila Sabeti, Markus Exner, Wolfgang Mlekusch, et al.
Thrombosis and Haemostasis|November 16, 2004
High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stentingMartin Schillinger, Markus Exner, Schila Sabeti, et al.
Research and Practice in Thrombosis and Haemostasis|July 12, 2019
The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis StudyHanna L Obermeier, Julia Riedl, Cihan Ay, et al.
Journal of Thrombosis and Haemostasis : JTH|February 20, 2020
Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective studyFlorian Posch, Julia Riedl, Eva-Maria Reitter, et al.
Journal of Thrombosis and Haemostasis : JTH|April 20, 2021
Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)Johannes Thaler, Cihan Ay, Karoline V Gleixner, et al.
Pageof 14

Showing results (71-80 of 134) with videos related to

Sort By:
Pageof 14
Blood|January 24, 2004
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolismSabine Eichinger, Verena Schönauer, Ansgar Weltermann, et al.
British Journal of Haematology|November 18, 2003
Is the determination of anti-beta2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome?Kety Hsieh, Paul Knöbl, Claudia Rintelen, et al.
JAMA|August 28, 2003
D-dimer levels and risk of recurrent venous thromboembolismSabine Eichinger, Erich Minar, Christine Bialonczyk, et al.
Biochemia Medica|September 14, 2017
Testing lupus anticoagulants in a real-life scenario - a retrospective cohort studyFranz Ratzinger, Tanja Panic, Helmuth Haslacher, et al.
Research and Practice in Thrombosis and Haemostasis|December 29, 2025
High prevalence of factor XIII deficiency and its association with bleeding in extracorporeal membrane oxygenation patients: an observational study from a prospectively compiled biobankAndrea Kornfehl, Roman Brock, Peter Quehenberger, et al.
Stroke|June 4, 2005
Prognostic impact of fibrinogen in carotid atherosclerosis: nonspecific indicator of inflammation or independent predictor of disease progression?Schila Sabeti, Markus Exner, Wolfgang Mlekusch, et al.
Thrombosis and Haemostasis|November 16, 2004
High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stentingMartin Schillinger, Markus Exner, Schila Sabeti, et al.
Research and Practice in Thrombosis and Haemostasis|July 12, 2019
The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis StudyHanna L Obermeier, Julia Riedl, Cihan Ay, et al.
Journal of Thrombosis and Haemostasis : JTH|February 20, 2020
Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective studyFlorian Posch, Julia Riedl, Eva-Maria Reitter, et al.
Journal of Thrombosis and Haemostasis : JTH|April 20, 2021
Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)Johannes Thaler, Cihan Ay, Karoline V Gleixner, et al.
Pageof 14